Figure 2 | Scientific Reports

Figure 2

From: Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack

Figure 2

Incremental cost-effectiveness scatterplot of the result of the probabilistic sensitivity analysis. The dashed line represents the willingness-to-pay threshold of CNY 105,000 per QALY. The white square represents the base-case (0.031 QALYs gained at an incremental cost of CNY 420.13). CNY, Chinese Yuan Renminbi; QALYs, quality adjusted life years; WTP, willingness-to-pay.

Back to article page